HealthcareServices

Theranostics Market Insights Report: Opportunities and Drivers 2030

March 3, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the theranostics market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Theranostics Market between 2026 and 2030?

The theranostics market size has seen rapid expansion in recent years. It is projected to increase from $122.98 billion in 2025 to $136.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. Historically, this growth can be attributed to advancements in molecular diagnostics, an increased prevalence of chronic diseases, the growth of oncology-focused research programs, the availability of targeted therapeutics, and the expansion of diagnostic laboratory infrastructure.

The theranostics market is anticipated to experience substantial expansion over the coming years. This market is projected to reach a value of $205.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. This projected increase is driven by factors such as growing investments in precision medicine, wider acceptance of AI-powered diagnostic instruments, the broadening scope of theranostic uses in oncology, increased incorporation of genomics into medical procedures, and a greater need for individualized treatment results. Key developments anticipated in the forecast period involve a heightened integration of diagnostics with targeted therapies, increased embrace of personalized medicine platforms, expanded application of molecular imaging techniques, growth in the creation of companion diagnostics, and a sharpened emphasis on treatment plans tailored to individual patients.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10823&type=smp

Which Drivers Are Expected To Impact The Theranostics Market During The Forecast Period?

The expanding occurrence of cancer is projected to stimulate the growth of the theranostics market moving forward. Cancer, characterized by uncontrolled cell multiplication, affects various organs and significantly contributes to illness and death globally. Theranostics, which unites therapeutic and diagnostic functions, holds considerable promise for managing cancer and other chronic conditions. This methodology facilitates personalized and precise treatments by integrating diagnostic insights with therapeutic actions, thereby creating avenues for innovation within the healthcare sector. Consequently, the growing population of cancer patients will fuel the expansion of the theranostics market. For example, in August 2024, the UK-based Macmillan Cancer Support reported that over 3 million individuals in the UK are living with cancer in 2024, with forecasts indicating an increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the escalating prevalence of cancer is propelling the theranostics market.

Which Segments Are Driving Activity In The Theranostics Market?

The theranostics market covered in this report is segmented –

1) By Disease Type: Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, Other Diseases

2) By Technology: Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, Other Technologies

3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Neurological Disorders: Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Epilepsy

2) By Cardiovascular Diseases: Coronary Artery Disease, Heart Failure, Atrial Fibrillation, Hypertension

3) By Immunological Disorders: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Psoriasis

4) By Oncology Diseases: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

5) By Other Diseases: Infectious Diseases, Metabolic Disorders, Genetic Disorders

How Are New Market Trends Shaping The Landscape Of The Theranostics Market?

Leading companies in the theranostics market are prioritizing the development of advanced technological solutions, such as theranostics clinical trials, to advance personalized medicine and enhance patient outcomes by merging diagnostics and therapeutics into a unified treatment approach. Theranostics clinical trials are research endeavors designed to assess the combined application of diagnostic tests and targeted therapies to customize treatment strategies for individual patients. These studies aim to ascertain the effectiveness of specific treatments based on patient-specific biomarkers, thereby strengthening personalized medicine initiatives. For instance, in May 2024, BAMF Health, a US-based cancer treatment center, inaugurated the COMBAT Trial, officially titled “A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617” (NCT05633160). Significant aspects include a swift activation process enabled by BAMF Health’s BAMF RapAct program, which facilitated the trial’s launch in merely seven weeks, and a concentrated effort on utilizing innovative radiopharmaceuticals aimed at the Gastrin-Releasing Peptide receptor (GRPR) to broaden treatment possibilities for patients with limited therapeutic avenues.

Which Major Firms Are Strengthening Their Position In The Theranostics Market?

Major companies operating in the theranostics market are Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Radiopharm Theranostics Ltd, Alpha-Theranostics, Cardio-Theranostics LLC, Curium, Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Bristol-Myers Squibb Company, Danaher Corporation, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/theranostics-global-market-report

Which Regions Are Poised For Strategic Growth In The Theranostics Market?

North America was the largest region in the global theranostics market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Theranostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10823&type=smp

Browse Through More Reports Similar to the Global Theranostics Market 2026, By The Business Research Company

Antidotes Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidotes-global-market-report

Radiopharmaceutical Theranostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-theranostics-global-market-report

Music Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795